TY - JOUR
T1 - Dapagliflozin monotherapy in drug-naïve patients with diabetes
T2 - a randomized-controlled trial of low-dose range
AU - Bailey, C.J.
AU - Iqbal, N.
AU - T'joen, C.
AU - List, J.F.
PY - 2012/10
Y1 - 2012/10
N2 - Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double-blind, placebo-controlled study assigned treatment-naïve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug-naïve with inadequate glycaemic control [haemoglobin A1c (HbA1c) =7.0 and =10.0%]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose (FPG), and proportions achieving HbA1c
AB - Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double-blind, placebo-controlled study assigned treatment-naïve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug-naïve with inadequate glycaemic control [haemoglobin A1c (HbA1c) =7.0 and =10.0%]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose (FPG), and proportions achieving HbA1c
KW - dapagliflozin
KW - diabetes mellitus
KW - glycaemic control
KW - SGLT2
KW - sodium-glucose co-transporter 2
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84866003015&partnerID=8YFLogxK
UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2012.01659.x/abstract
U2 - 10.1111/j.1463-1326.2012.01659.x
DO - 10.1111/j.1463-1326.2012.01659.x
M3 - Article
AN - SCOPUS:84866003015
SN - 1462-8902
VL - 14
SP - 951
EP - 959
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 10
ER -